We are developing
A single platform for defeating cancer and much more.
A single platform for defeating cancer
We are HEPHAISTOS-Pharma
A preclinical stage Biotech company developing the next generation of oncology treatments that will boost the immune system to treat incurable cancers.
One need, one mission :
Immunotherapies have shown impressive results in the past years, by treating cancers like never before. Unfortunately, success level are still very low and only 10% of patients can be cured today.
Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients’ immune response and turning hidden “cold” tumors into “hot” targets for our immune system.
Team
Board Members
Scientific Advisory Board
Market Needs
Turning cold tumors into hot tumors
Only 10% of current immunotherapies are successful
Need for stronger and safer immuno-modulators
to turn cold tumors into hot tumors and improve cancer therapy
Innovation & advantages
Onco-Boost platform
ONCO-Boost is the First-In-Class Immunostimulant injectable intravenously, able to treat metastatic and hardly accessible cancer like Osteorsarcoma
Mechanism of Action
Mechanism of Action (MoA)
ONCO-Boost
will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.
Monoclonal
Antibody (mAb)
will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumors as targets to destroy.
All together
By recruiting and stimulating immune cells, ONCO-Boost enables the treatment of tumors that were not previously sensitive to mAb’s action and opens the way to treat incurable cancers.
Publications
Pipeline
News
HEPHAISTOS secures €10.3 M to reach the clinical stage
HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round,…
Frederic CAROFF will attend BIO Europe Spring in Barcelona
Our CEO, Frederic CAROFF will be attending BIO-Europe…
HEPHAISTOS-Pharma secures a €2 million seed round
HEPHAISTOS-Pharma secures a €2 million seed round with…
HEPHAISTOS Laureate of the SANOFI Golden Ticket mRNA
🏆 We are pleased to announce that…
Media coverage
25 January 2024
02 November 2020
Clusters & Partners
Financial Supports
HEPHAISTOS-Pharma is financed by the European Union FEDER regional fund
HEPHAISTOS-Pharma is financed by the WILCO Healthcare startup cluster.
HEPHAISTOS-Pharma is financed by the European Union and aims at becoming a breakthrough innovative Biotech in oncology, reaching clinical Phase 1 within 2 years. The ONCO-Boost project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868937
HEPHAISTOS-Pharma’s academic partner CRCL is financed by the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.